PubMed Review
December 2022
PubMed Review of the Most relevant research on Lung Cancer
SCREENING, DIAGNOSIS, BIOMARKER TESTING, AND STAGING
Patterns of Extrathoracic Metastasis in Lung Cancer Patients Park HK, Han J, Kwon GY, Yeo MK, Bae GE. Patterns of Extrathoracic Metastasis in Lung Cancer Patients. Curr Oncol. 2022;29(11):8794-8801. Published 2022 Nov 16. doi:10.3390/curroncol29110691
Cross modality fusion for modality-specific lung tumor segmentation in PET-CT images Zhang X, Zhang B, Deng S, Meng Q, Chen X, Xiang D. Cross modality fusion for modality-specific lung tumor segmentation in PET-CT images. Phys Med Biol. 2022;67(22):10.1088/1361-6560/ac994e. Published 2022 Nov 7. doi:10.1088/1361-6560/ac994e
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer Wang X, Ricciuti B, Alessi JV, et al. Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2021;113(12):1761-1769. doi:10.1093/jnci/djab116
Receipt of Recommended Follow-up Care After a Positive Lung Cancer Screening Examination Rivera MP, Durham DD, Long JM, et al. Receipt of Recommended Follow-up Care After a Positive Lung Cancer Screening Examination. JAMA Netw Open. 2022;5(11):e2240403. Published 2022 Nov 1. doi:10.1001/jamanetworkopen.2022.40403
Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework-Driven Systematic Review Sedani AE, Davis OC, Clifton SC, Campbell JE, Chou AF. Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework-Driven Systematic Review. J Natl Cancer Inst. 2022;114(11):1449-1467. doi:10.1093/jnci/djac154
Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force
Liu Y, Pan IE, Tak HJ, Vlahos I, Volk R, Shih YT. Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force. JAMA Netw Open. 2022;5(11):e2243163. Published 2022 Nov 1. doi:10.1001/jamanetworkopen.2022.43163
Barriers and facilitators for low-dose computed tomography lung cancer screening in rural populations in the United States: a scoping review protocolPalokas M, Hinton E, Duhe R, et al. Barriers and facilitators for low-dose computed tomography lung cancer screening in rural populations in the United States: a scoping review protocol. JBI Evid Synth. 2022;20(11):2727-2733. Published 2022 Nov 1. doi:10.11124/JBIES-21-00337
Impact of Low-dose Chest CT Screening on the Association Between Rurality and Lung Cancer Outcomes Hinojos M, Li X, Mikesell S, et al. Impact of Low-dose Chest CT Screening on the Association Between Rurality and Lung Cancer Outcomes. Am J Clin Oncol. 2022;45(12):519-525. doi:10.1097/COC.0000000000000956
A handheld electronic device with the potential to detect lung cancer biomarkers from exhaled breath Emam S, Nasrollahpour M, Allen JP, et al. A handheld electronic device with the potential to detect lung cancer biomarkers from exhaled breath. Biomed Microdevices. 2022;24(4):41. Published 2022 Nov 18. doi:10.1007/s10544-022-00638-8
Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience Phan C, Jespersen F, Weipert C, Li T, Yoneda KY. Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience. Ther Adv Respir Dis. 2022;16:17534666221135324. doi:10.1177/17534666221135324
Dynamic Risk Prediction of 30-Day Mortality in Patients With Advanced Lung Cancer: Comparing Five Machine Learning Approaches Vesteghem C, Szejniuk WM, Brøndum RF, Falkmer UG, Azencott CA, Bøgsted M. Dynamic Risk Prediction of 30-Day Mortality in Patients With Advanced Lung Cancer: Comparing Five Machine Learning Approaches. JCO Clin Cancer Inform. 2022;6:e2200054. doi:10.1200/CCI.22.00054
The usefulness of liquid-based cytology of bronchoalveolar lavage fluid combined with bronchial brush specimens in lung cancer diagnosis Ma S, Yu X, Jin X, et al. The usefulness of liquid-based cytology of bronchoalveolar lavage fluid combined with bronchial brush specimens in lung cancer diagnosis. J Int Med Res. 2022;50(11):3000605221132708. doi:10.1177/03000605221132708
Comparing modalities for risk assessment in patients with pulmonary lesions and nondiagnostic bronchoscopy for suspected lung cancer Yu DH, Shafiq M, Batra H, et al. Comparing modalities for risk assessment in patients with pulmonary lesions and nondiagnostic bronchoscopy for suspected lung cancer. BMC Pulm Med. 2022;22(1):442. Published 2022 Nov 24. doi:10.1186/s12890-022-02181-x
Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening Fortunato O, Huber V, Segale M, et al. Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening. Cancer Epidemiol Biomarkers Prev. 2022;31(11):2020-2029. doi:10.1158/1055-9965.EPI-22-0689
EBUS-TBNA in Extrathoracic Malignancies: Diagnostic and Prognostic Implications Martin-Deleon R, Solarat B, Moisés J, et al. EBUS-TBNA in Extrathoracic Malignancies: Diagnostic and Prognostic Implications. Lung. 2022;200(6):747-753. doi:10.1007/s00408-022-00584-5
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy Poulikakos PI, Sullivan RJ, Yaeger R. Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clin Cancer Res. 2022;28(21):4618-4628. doi:10.1158/1078-0432.CCR-21-2138
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy Botticelli A, Pomati G, Cirillo A, et al. The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Front Immunol. 2022;13:974087. Published 2022 Nov 3. doi:10.3389/fimmu.2022.974087
Preoperative blood markers for prediction of recurrence-free survival after surgical treatment of patients with stage III lung adenocarcinoma Tahanovich AD, Kauhanka NN, Murashka DI, et al. Preoperative blood markers for prediction of recurrence-free survival after surgical treatment of patients with stage III lung adenocarcinoma. Klin Lab Diagn. 2022;67(11):640-646. doi:10.51620/0869-2084-2022-67-11-640-646
ACR Appropriateness Criteria® Malignant or Aggressive Primary Musculoskeletal Tumor-Staging and Surveillance: 2022 Update Expert Panel on Musculoskeletal Imaging, Stanborough R, Demertzis JL, et al. ACR Appropriateness Criteria® Malignant or Aggressive Primary Musculoskeletal Tumor-Staging and Surveillance: 2022 Update. J Am Coll Radiol. 2022;19(11S):S374-S389. doi:10.1016/j.jacr.2022.09.015
NSCLC SURGERY
Pulmonary function changes after sublobar resection in patients with peripheral non-subpleural nodules Feng KP, Shen ZQ, Xu C, et al. Pulmonary function changes after sublobar resection in patients with peripheral non-subpleural nodules. BMC Surg. 2022;22(1):390. Published 2022 Nov 11. doi:10.1186/s12893-022-01828-0
Impact of Central Airway Infiltration Type in Primary Lung Cancer Patients Treated With Sleeve Lobectomy Tsukioka T, Izumi N, Komatsu H, et al. Impact of Central Airway Infiltration Type in Primary Lung Cancer Patients Treated With Sleeve Lobectomy. In Vivo. 2022;36(6):2981-2985. doi:10.21873/invivo.13042
Mortality and lung function decline in patients who develop chronic pulmonary aspergillosis after lung cancer surgery Kim BG, Choi YS, Shin SH, et al. Mortality and lung function decline in patients who develop chronic pulmonary aspergillosis after lung cancer surgery. BMC Pulm Med. 2022;22(1):436. Published 2022 Nov 22. doi:10.1186/s12890-022-02253-y
Surgery versus radiotherapy in octogenarians with stage Ia non‑small cell lung cancer: propensity score matching analysis of the SEER database Ni L, Lin G, Zhang Z, Sun D, Liu Z, Liu X. Surgery versus radiotherapy in octogenarians with stage Ia non‑small cell lung cancer: propensity score matching analysis of the SEER database. BMC Pulm Med. 2022;22(1):411. Published 2022 Nov 10. doi:10.1186/s12890-022-02177-7
Aggressive histological component in subsolid lung adenocarcinoma: priority for resection without delay Yotsukura M, Nakagawa K, Takemura C, et al. Aggressive histological component in subsolid lung adenocarcinoma: priority for resection without delay. Jpn J Clin Oncol. 2022;52(11):1321-1326. doi:10.1093/jjco/hyac131
The perioperative outcomes of uniport versus two-port and three-port video-assisted thoracoscopic surgery in lung cancer: a systematic review and meta-analysis Cheng YF, Huang CL, Hung WH, Cheng CY, Wang BY. The perioperative outcomes of uniport versus two-port and three-port video-assisted thoracoscopic surgery in lung cancer: a systematic review and meta-analysis. J Cardiothorac Surg. 2022;17(1):284. Published 2022 Nov 8. doi:10.1186/s13019-022-02034-y
Comparison of the geriatric nutritional risk index and the prognostic nutritional index in determining survival outcome in patients with non-small cell lung cancer undergoing surgical resection: A cohort study An S, Han GY, Eo W, Kim DH, Lee S. Comparison of the geriatric nutritional risk index and the prognostic nutritional index in determining survival outcome in patients with non-small cell lung cancer undergoing surgical resection: A cohort study. Medicine (Baltimore). 2022;101(45):e31591. doi:10.1097/MD.0000000000031591
Is video-assisted thoracoscopic surgery comparable with thoracotomy in perioperative and long-term survival outcomes for non-small-cell lung cancer after neoadjuvant treatment? Wang YF, Deng HY, Huang W, Zhou Q. Is video-assisted thoracoscopic surgery comparable with thoracotomy in perioperative and long-term survival outcomes for non-small-cell lung cancer after neoadjuvant treatment?. Interact Cardiovasc Thorac Surg. 2022;35(6):ivac271. doi:10.1093/icvts/ivac271
Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review) Su XE, Hong WP, He HF, et al. Recent advances in postoperative pulmonary rehabilitation of patients with non‑small cell lung cancer (Review). Int J Oncol. 2022;61(6):156. doi:10.3892/ijo.2022.5446
Sleeve lobectomy in patients with non-small-cell lung cancer: a report from the European Society of Thoracic Surgery database 2021 Gonzalez M, Chriqui LE, Décaluwé H, et al. Sleeve lobectomy in patients with non-small-cell lung cancer: a report from the European Society of Thoracic Surgery database 2021. Eur J Cardiothorac Surg. 2022;62(6):ezac502. doi:10.1093/ejcts/ezac502
Operating time: an independent and modifiable risk factor for short-term complications after video-thoracoscopic pulmonary lobectomy Gómez-Hernández MT, Forcada C, Varela G, Jiménez MF; Spanish Group of Video-assisted Thoracic Surgery (GEVATS). Operating time: an independent and modifiable risk factor for short-term complications after video-thoracoscopic pulmonary lobectomy. Eur J Cardiothorac Surg. 2022;62(6):ezac503. doi:10.1093/ejcts/ezac503
Application of bilateral simultaneous sequential single-incision video-assisted thoracic surgery in multiple nodules both lungs: a single-center experience of 10 cases Shi W, Hu Y, Chang G, et al. Application of bilateral simultaneous sequential single-incision video-assisted thoracic surgery in multiple nodules both lungs: a single-center experience of 10 cases. BMC Surg. 2022;22(1):386. Published 2022 Nov 10. doi:10.1186/s12893-022-01841-3
Identification of the intersegmental plane by arterial ligation method during thoracoscopic segmentectomy He H, Zhao H, Ma L, et al. Identification of the intersegmental plane by arterial ligation method during thoracoscopic segmentectomy. J Cardiothorac Surg. 2022;17(1):281. Published 2022 Nov 4. doi:10.1186/s13019-022-02011-5
The left upper lobe challenge in video-assisted thoracoscopic surgery-use of a composite score to improve the assessment of simulated lobectomy Haidari TA, Bjerrum F, Grimstrup S, et al. The left upper lobe challenge in video-assisted thoracoscopic surgery-use of a composite score to improve the assessment of simulated lobectomy. Eur J Cardiothorac Surg. 2022;62(6):ezac465. doi:10.1093/ejcts/ezac465
Can the Risk Analysis Index for Frailty Predict Morbidity and Mortality in Patients Undergoing High-risk Surgery? Wan MA, Clark JM, Nuño M, Cooke DT, Brown LM. Can the Risk Analysis Index for Frailty Predict Morbidity and Mortality in Patients Undergoing High-risk Surgery?. Ann Surg. 2022;276(6):e721-e727. doi:10.1097/SLA.0000000000004626
NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations Hsu PC, Chang JW, Chang CF, et al. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations. Ther Adv Respir Dis. 2022;16:17534666221132731. doi:10.1177/17534666221132731
Two New Drugs Approved for Non-Small Cell Lung Cancer Aschenbrenner DS. Two New Drugs Approved for Non-Small Cell Lung Cancer. Am J Nurs. 2022;122(12):22-23. doi:10.1097/01.NAJ.0000904080.71037.14
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer Lee A. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer [published correction appears in Target Oncol. 2022 Dec 2;:]. Target Oncol. 2022;17(6):727-733. doi:10.1007/s11523-022-00922-w
Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Parums DV. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Med Sci Monit. 2022;28:e938746. Published 2022 Nov 1. doi:10.12659/MSM.938746
Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer Xu L, Shi M, Wang S, et al. Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer. Front Immunol. 2022;13:1009621. Published 2022 Oct 25. doi:10.3389/fimmu.2022.1009621
Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion He D, Guo Z, Xie Z, Zhang Y, Deng Q, Yang H. Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion. Can Respir J. 2022;2022:6763625. Published 2022 Oct 31. doi:10.1155/2022/6763625
Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials Wang BC, Kuang BH, Liu XX, Lin GH. Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials. Medicine (Baltimore). 2022;101(44):e31337. doi:10.1097/MD.0000000000031337
Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer populationYu X, Zhao L, Song B. Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population. BMC Pulm Med. 2022;22(1):431. Published 2022 Nov 21. doi:10.1186/s12890-022-02210-9
Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab Dey A, Austin M, Kluger HM, et al. Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. Front Immunol. 2022;13:1026964. Published 2022 Nov 3. doi:10.3389/fimmu.2022.1026964
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options Brazel D, Kroening G, Nagasaka M. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs. 2022;36(6):717-729. doi:10.1007/s40259-022-00556-4
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study Chihara Y, Takeda T, Goto Y, et al. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study. Oncologist. 2022;27(11):903-e834. doi:10.1093/oncolo/oyac193
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies Andrini E, Federico AD, Sisi M, et al. Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Immunotherapy. 2022;14(16):1329-1340. doi:10.2217/imt-2022-0060
The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study Leiter A, Kong CY, Gould MK, et al. The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. PLoS One. 2022;17(11):e0263911. Published 2022 Nov 15. doi:10.1371/journal.pone.0263911
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy Hsu ML, Murray JC, Psoter KJ, et al. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. Oncologist. 2022;27(11):971-981. doi:10.1093/oncolo/oyac140
Gastrointestinal toxicity of systemic oncology immunotherapy Bureš J, Kohoutová D, Zavoral M. Gastrointestinal toxicity of systemic oncology immunotherapy. Gastrointestinální toxicita systémové onkologické imunoterapie. Klin Onkol. 2022;35(5):346-357. doi:10.48095/ccko2022346
First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis Tao J, Zheng C, Zhang C, et al. First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis. J Int Med Res. 2022;50(11):3000605221132703. doi:10.1177/03000605221132703
A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer Liu XX, Lin GH, Wang BC. A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. Medicine (Baltimore). 2022;101(45):e31751. doi:10.1097/MD.0000000000031751
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib Yin Y, Shu Y, Zhu J, Li F, Li J. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. Sci Rep. 2022;12(1):19555. Published 2022 Nov 15. doi:10.1038/s41598-022-23834-1
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study Xing P, Zhao Q, Zhang L, et al. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. BMC Med. 2022;20(1):453. Published 2022 Nov 23. doi:10.1186/s12916-022-02646-0
Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation He W, Cao X, Kong K, Rong K, Han S, Qin A. Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation. Front Endocrinol (Lausanne). 2022;13:939959. Published 2022 Nov 8. doi:10.3389/fendo.2022.939959
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing Jones L, Rittberg R, Leung B, et al. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing. Curr Oncol. 2022;29(11):8686-8692. Published 2022 Nov 15. doi:10.3390/curroncol29110685
Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study Diel IJ, Greil R, Janssen J, et al. Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. Support Care Cancer. 2022;30(11):9267-9278. doi:10.1007/s00520-022-07333-7
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer Yoshida R, Saigi M, Tani T, et al. MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer. Cancer Res. 2022;82(21):4079-4092. doi:10.1158/0008-5472.CAN-22-0770
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies Rivas S, Marín A, Samtani S, González-Feliú E, Armisén R. MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies. Int J Mol Sci. 2022;23(22):13898. Published 2022 Nov 11. doi:10.3390/ijms232213898
The Efficacy of Fosbretabulin Disodium Combined with Radiofrequency Ablation in Lung Cancer Kou J, Liu J, Gu X, Liu N. The Efficacy of Fosbretabulin Disodium Combined with Radiofrequency Ablation in Lung Cancer. Radiat Res. 2022;198(5):467-474. doi:10.1667/RADE-21-00242.1
NSCLC - RADIOTHERAPY
Risk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study Yang S, Huang S, Ye X, Xiong K, Zeng B, Shi Y. Risk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study. BMC Pulm Med. 2022;22(1):402. Published 2022 Nov 7. doi:10.1186/s12890-022-02211-8
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial Olson R, Jiang W, Liu M, et al. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial. JAMA Oncol. 2022;8(11):1644-1650. doi:10.1001/jamaoncol.2022.4394
Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND Sherry AD, Bathala TK, Liu S, et al. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys. 2022;114(5):910-918. doi:10.1016/j.ijrobp.2022.05.023
Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer Kim KH, Oh J, Yang G, et al. Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer. JAMA Oncol. 2022;8(11):1624-1634. doi:10.1001/jamaoncol.2022.4202
Radiation treatment response and hypoxia biomarkers revealed by machine learning assisted Raman spectroscopy in tumour cells and xenograft tissues Deng X, Milligan K, Brolo A, Lum JJ, Andrews JL, Jirasek A. Radiation treatment response and hypoxia biomarkers revealed by machine learning assisted Raman spectroscopy in tumour cells and xenograft tissues. Analyst. 2022;147(22):5091-5104. Published 2022 Nov 7. doi:10.1039/d2an01222g
Everything You Always Wanted to Know about Sarcopenia but Were Afraid to Ask: A Quick Guide for Radiation Oncologists (Impact of Sarcopenia in Radiotherapy: The AFRAID Project) Medici F, Rizzo S, Buwenge M, et al. Everything You Always Wanted to Know about Sarcopenia but Were Afraid to Ask: A Quick Guide for Radiation Oncologists (Impact of Sarcopenia in Radiotherapy: The AFRAID Project). Curr Oncol. 2022;29(11):8513-8528. Published 2022 Nov 8. doi:10.3390/curroncol29110671
SMALL CELL LUNG CANCER - SCLC
Galectin-1, a novel promising target for outcome prediction and treatment in SCLC Corral JM, Puerto-Nevado LD, Cedeño M, et al. Galectin-1, a novel promising target for outcome prediction and treatment in SCLC. Biomed Pharmacother. 2022;156:113987. doi:10.1016/j.biopha.2022.113987
Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory Kashima J, Okuma Y. Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory. Semin Cancer Biol. 2022;86(Pt 2):386-395. doi:10.1016/j.semcancer.2022.05.005
Low level of complement factor H increases the risk of cancer-related death in patients with small-cell lung cancer Xiang M, Zhang H, Kou L, Chen J, Xu Z, He J. Low level of complement factor H increases the risk of cancer-related death in patients with small-cell lung cancer. Postgrad Med J. 2022;98(1166):919-924. doi:10.1136/postgradmedj-2021-141186
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset Febres-Aldana CA, Chang JC, Ptashkin R, et al. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clin Cancer Res. 2022;28(21):4702-4713. doi:10.1158/1078-0432.CCR-22-1115
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol Asao T, Watanabe S, Tanaka T, Morita S, Kobayashi K. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol. BMC Cancer. 2022;22(1):1135. Published 2022 Nov 4. doi:10.1186/s12885-022-10222-1
PALLIATIVE AND SUPPORTIVE CARE
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling Caccialanza R, Cereda E, Agustoni F, et al. Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. BMC Cancer. 2022;22(1):1212. Published 2022 Nov 24. doi:10.1186/s12885-022-10296-x
Vocal cord augmentation in a palliative setting for patients with lung cancer and mediastinal involvement Lauridsen UM, Schultz JDJH, Nyhus CH, Sørensen JR. Vocal cord augmentation in a palliative setting for patients with lung cancer and mediastinal involvement. Ugeskr Laeger. 2022;184(47):V05220332.
A Randomized Trial of a Nurse-Led Palliative Care Intervention for Patients with Newly Diagnosed Lung Cancer Reinke LF, Sullivan DR, Slatore C, et al. A Randomized Trial of a Nurse-Led Palliative Care Intervention for Patients with Newly Diagnosed Lung Cancer. J Palliat Med. 2022;25(11):1668-1676. doi:10.1089/jpm.2022.0008
Smoking Cessation Interventions Gaddey HL, Dakkak M, Jackson NM. Smoking Cessation Interventions. Am Fam Physician. 2022;106(5):513-522.
Video and In-Person Palliative Care Delivery Challenges before and during the COVID-19 Pandemic Chua IS, Olmsted M, Plotke R, et al. Video and In-Person Palliative Care Delivery Challenges before and during the COVID-19 Pandemic. J Pain Symptom Manage. 2022;64(6):577-587. doi:10.1016/j.jpainsymman.2022.08.005
Effects of a yoga-based stress reduction intervention on stress, psychological outcomes and cardiometabolic biomarkers in cancer caregivers: A randomized controlled trial Lee LJ, Shamburek R, Son H, et al. Effects of a yoga-based stress reduction intervention on stress, psychological outcomes and cardiometabolic biomarkers in cancer caregivers: A randomized controlled trial. PLoS One. 2022;17(11):e0277009. Published 2022 Nov 10. doi:10.1371/journal.pone.0277009
COMPLEMENTARY & ALTERNATIVE THERAPY
Phytochemistry, allelopathy and anticancer potentiality of Withania somnifera (L.) Dunal (Solanaceae) Ahmed HA, El-Darier SM. Phytochemistry, allelopathy and anticancer potentiality of Withania somnifera (L.) Dunal (Solanaceae). Braz J Biol. 2022;84:e263815. Published 2022 Nov 4. doi:10.1590/1519-6984.263815
MISCELLANEOUS WORKS
Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016 Brouwer AF, Engle JM, Jeon J, Meza R. Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016. J Natl Cancer Inst. 2022;114(11):1492-1500. doi:10.1093/jnci/djac144
Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience Che W, Liu J, Fu T, Wang X, Lyu J. Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience. Curr Oncol. 2022;29(11):8374-8389. Published 2022 Nov 2. doi:10.3390/curroncol29110660
Body mass index and incidence of lung cancer in the HUNT study: using observational and Mendelian randomization approaches Jiang L, Sun YQ, Brumpton BM, Langhammer A, Chen Y, Mai XM. Body mass index and incidence of lung cancer in the HUNT study: using observational and Mendelian randomization approaches. BMC Cancer. 2022;22(1):1152. Published 2022 Nov 8. doi:10.1186/s12885-022-10215-0
COVID-19 Candidate Genes and Pathways Potentially Share the Association with Lung Cancer Alnajeebi AM, Alharbi HFH, Alelwani W, et al. COVID-19 Candidate Genes and Pathways Potentially Share the Association with Lung Cancer. Comb Chem High Throughput Screen. 2022;25(14):2463-2472. doi:10.2174/1386207324666210712092649
Small nodules (≤ 6 mm in diameter) of multiple primary lung cancers: prevalence and management Cheng H, Li WH, Li XJ, et al. Small nodules (≤ 6 mm in diameter) of multiple primary lung cancers: prevalence and management. J Cardiothorac Surg. 2022;17(1):278. Published 2022 Nov 1. doi:10.1186/s13019-022-02022-2
Leveraging the Clinical Timepoints in Lung Cancer Screening to Engage Individuals in Tobacco Treatment Park ER, Neil JM, Noonan E, et al. Leveraging the Clinical Timepoints in Lung Cancer Screening to Engage Individuals in Tobacco Treatment. JNCI Cancer Spectr. 2022;6(6):pkac073. doi:10.1093/jncics/pkac073
A population-based study on social inequality and barriers to healthcare-seeking with lung cancer symptoms Sætre LMS, Rasmussen S, Balasubramaniam K, Søndergaard J, Jarbøl DE. A population-based study on social inequality and barriers to healthcare-seeking with lung cancer symptoms. NPJ Prim Care Respir Med. 2022;32(1):48. Published 2022 Nov 5. doi:10.1038/s41533-022-00314-7
Accelerating integration of tobacco use treatment in the context of lung cancer screening: Relevance and application of implementation science to achieving policy and practice Shelley D, Wang VH, Taylor K, et al. Accelerating integration of tobacco use treatment in the context of lung cancer screening: Relevance and application of implementation science to achieving policy and practice. Transl Behav Med. 2022;12(11):1076-1083. doi:10.1093/tbm/ibac076
The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center Kasymjanova G, Rizzolo A, Pepe C, et al. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. Curr Oncol. 2022;29(11):8677-8685. Published 2022 Nov 14. doi:10.3390/curroncol29110684
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment Ramagopalan SV, Popat S, Gupta A, et al. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. JAMA Netw Open. 2022;5(11):e2239874. Published 2022 Nov 1. doi:10.1001/jamanetworkopen.2022.39874
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics Islami F, Ward EM, Sung H, et al. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. J Natl Cancer Inst. 2021;113(12):1648-1669. doi:10.1093/jnci/djab131
The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma Paajanen J, Bueno R, De Rienzo A. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma. Int J Mol Sci. 2022;23(21):13422. Published 2022 Nov 3. doi:10.3390/ijms232113422
Estimation of the Number of Individuals Living With Metastatic Cancer in the United States Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A. Estimation of the Number of Individuals Living With Metastatic Cancer in the United States. J Natl Cancer Inst. 2022;114(11):1476-1483. doi:10.1093/jnci/djac158
Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening Joung RH, Mullett TW, Kurtzman SH, et al. Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening. JAMA Netw Open. 2022;5(11):e2242354. Published 2022 Nov 1. doi:10.1001/jamanetworkopen.2022.42354
The burden and impact of chronic cough in severe disease Emilsson ÖI. The burden and impact of chronic cough in severe disease. Curr Opin Support Palliat Care. 2022;16(4):183-187. doi:10.1097/SPC.0000000000000623
Management of Cancer Patients in the COVID-19 Crisis Using Telemedicine: A Systematic Review Salehi F, Mashhadi L, Khazeni K, Ebrahimi Z. Management of Cancer Patients in the COVID-19 Crisis Using Telemedicine: A Systematic Review. Stud Health Technol Inform. 2022;299:118-125. doi:10.3233/SHTI220969
Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures Zhang Y, Cerullo M, Esposito A, Golla V. Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures. J Natl Compr Canc Netw. 2022;20(11):1215-1222.e1. doi:10.6004/jnccn.2022.7057
